Overview
Lilly’s Synthetic Molecule Design and Development (SMDD) is involved in key activities for the development of active pharmaceutical ingredients and formulated drug products from pre-clinical phases through commercialization of drug substances and drug products for small molecules, synthetic oligonucleotides, and synthetic peptides. Our scientists develop key technical and business solutions across the portfolio using their deep technical expertise to speed up testing of clinical hypothesis and overall drug development.